Answers are grounded in this paper and cite their sources.
Objective: To develop and validate a robust and stability-indicating RP-HPLC method for the simultaneous estimation of Saquinavir and Tipranavir in pharmaceutical formulations using an Analytical Quality by Design (AQbD) approach. Methods: Chromatographic conditions were optimized using a Box–Behnken design by evaluating mobile phase composition, buffer pH and flow rate as critical method parameters. The optimized method employed a Inertsil C18 column (250 mm × 4.6 mm, 5 µm particle size) with methanol and phosphate buffer (65:35, v/v; pH 3.5) at a flow rate of 1.0 ml/min and detection at 248 nm. The method was validated according to ICH Q2(R1) guidelines for specificity, linearity, accuracy, precision, sensitivity, robustness, and stability-indicating capability. Forced-degradation studies were performed under different stress conditions. ² values of 0.9992 for Saquinavir and 0.9995 for Tipranavir. Accuracy was satisfactory, with recoveries of 98–102%, while precision showed %RSD values below 2%. The method exhibited good sensitivity with low detection and quantification limits. Forced-degradation studies demonstrated effective separation of degradation products from the drug peaks, confirming the stability-indicating capability. The method remained Results: The method showed excellent linearity with r reliable under deliberate variations in chromatographic conditions. Conclusion: The developed AQbD-based RP-HPLC method was successfully validated and demonstrated satisfactory specificity, linearity, accuracy, precision, sensitivity, robustness, and stability-indicating capability. The method is suitable for routine quality control and stability assessment of Saquinavir and Tipranavir in pharmaceutical formulations.
No takes yet. Share an insight, caveat, or question.
USHASREE et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: